Suven Life bags product patents in China and Mexico

The Hyderabad-based Suven Life Sciences Ltd has received product patent from China and Mexico corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. Patents are valid through 2032 and 2031 in China and Mexico respectively.
 
The granted claims of the patents are from the mechanism of action include the class of selective H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, major depressive disorder (MDD), Parkinson and Schizophrenia.
   
With these new patents, Suven has a total of twenty one granted patents from China and twenty two granted patents from Mexico.